Technical analysis video on NASDAQ’s biotech penny stock OXiGENE Inc. (OXGN)
OXiGENE’s ZYBRESTAT targeted multi-billion markets for non-small cell lung and ovarian cancer, and also it is developing for the treatment of ophthalmological diseases and conditions such as the wet form of age-related macular degeneration (ARMD) and polypoidal choroidal neovascularization (PCV).